Yam Code

New Paste Browse

https://www.selleckchem.com/products/dl-buthionine-sulfoximine.html 4 months (95% confidence interval [CI] 6.5, 8.8) with abemaciclib and 7.8 months (95% CI 6.4, 9.5) with erlotinib (hazard ratio [HR] = 0.968 [95% CI 0.768, 1.219]; p = .77). Median PFS was 3.6 months (95% CI 2.8, 3.8) with abemaciclib and 1.9 months (95% CI 1.9, 2.0) with erlotinib (HR = 0.583 [95% CI 0.470, 0.723]; p <.000001). ORR was 8.9% and 2.7% (p = .010), and the disease control rate was 54.4% and 31.7% (p <.001) with abemaciclib and erlotinib, respectively. Safety results reflected the known safety profiles of abemaciclib and erlotinib. In this study, the primary endpoint of OS was not met; PFS and ORR were improved with manageable toxicity in the abemaciclib arm. The increases in response rates and PFS support further investigation of abemaciclib in other NSCLC subpopulations or in combination with other agents. www.ClinicalTrials.gov, identifier NCT02152631. www.ClinicalTrials.gov, identifier NCT02152631. Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) portends a worse prognosis. The objective of this study was to compare the efficacy of percutaneous radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) plus sorafenib to that of the most commonly utilized regimen of TACE plus sorafenib in large HCCs with type I/II PVTT. An open-label, single-center, prospective, randomized trial of participants with tumors ≥5 cm and type I/II PVTT was performed. Participants with previously untreated HCCs were divided into two groups RFA + cTACE + sorafenib (study group, n = 40) and cTACE + sorafenib (control group, n = 40). The primary endpoint was the objective response rate (ORR), the secondary endpoints included the overall survival (OS); time to progression (TTP); and toxicity. Prognostic factors were analyzed using cox-regression analysis. 80 patients were enrolled into this study with integrated clinical data. Under a median follow-up of 506 days,

Paste Settings

Paste Title : [Optional]

Paste Folder : [Optional]

Syntax Highlighting : [Optional]

Paste Expiration : [Optional]

Paste Status : [Optional]

Password : [Optional]

Description: [Optional]

Tags: [Optional]

Encrypt Paste (?)

You are currently not logged in, this means you can not edit or delete anything you paste. Sign Up or Login

Paste Settings

Site Languages